Cargando...
Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report
Osimertinib is a novel, irreversible, mutant‐selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR mutations and the EGFR T790 mutation. Here, we report a woman with EGFR‐mutated lung adenocarcinoma who, after 23‐month treatment with gefitinib, developed the EGFR...
Gardado en:
| Publicado en: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5879057/ https://ncbi.nlm.nih.gov/pubmed/29411527 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12596 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|